|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2002-05-21 |
A Double Blind Controlled Clinical Study to Investigate the Efficacy and Tolerability of Subcutaneous Treprostinil Sodium in Patients With Severe Non-operable Chronic Thromboembolic Pulmonary Hypertension (CTREPH)
The primary purpose of this study is to determine the effect on six-minute walking test (6MWT) distance after 24 weeks treatment with subcutaneous (SC) Treprostinil Sodium in patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension.
100 项与 SciPharm SARL 相关的临床结果
0 项与 SciPharm SARL 相关的专利(医药)
100 项与 SciPharm SARL 相关的药物交易
100 项与 SciPharm SARL 相关的转化医学